

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA BIOTECH SERVICES HOLDINGS LIMITED**

**中國生物科技服務控股有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

### **RETIREMENT AND PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND PROPOSED CHANGE OF COMPOSITION OF BOARD COMMITTEES**

#### **RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from the conclusion of the forthcoming annual general meeting of the Company (the “**AGM**”), Dr. Ho Ivan Chun Kit (“**Dr. Ho**”) will retire from his position as an independent non-executive Director, a member of each of the audit committee (the “**Audit Committee**”), the nomination committee (the “**Nomination Committee**”) and remuneration committee (the “**Remuneration Committee**”) of the Company due to Dr. Ho’s intention to devote more time to his other business and personal engagements.

Dr. Ho has confirmed that he has no disagreement with the Board, and the Board and Dr. Ho are not aware of any matters relating to his retirement that need to be brought to the attention of the Stock Exchange and the shareholders of the Company (the “**Shareholders**”). The Board would like to take this opportunity to express its sincere gratitude to Dr. Ho for his valuable contributions to the Company during his tenure of service.

## **PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND PROPOSED CHANGE OF COMPOSITION OF BOARD COMMITTEES**

Dr. Guo Yuantao (“**Dr. Guo**”) has been proposed by the Board to be elected and appointed as an independent non-executive Director and a relevant ordinary resolution will be put forward at the AGM for Shareholders’ consideration and approval. If the proposed appointment is approved at the AGM, Dr. Guo shall become a member of the Audit Committee, Nomination Committee and Remuneration Committee following her appointment as an independent non-executive Director becoming effective.

The biographical details of Dr. Guo are set out below:

Dr. Guo Yuantao (郭圓濤), aged 50, has over 20 years of equity research experience in various international investment banks with both sector exposure and macro exposure. Dr. Guo was the former Chief Strategist and Economist, Head of Equity Research and Managing Director of the China Merchants Securities (Hong Kong) from 2017 to 2023. Prior to joining China Merchants Securities (Hong Kong), Dr. Guo was the former Head of Asia Consumer/Internet/Media Equity, Research and Managing Director of Jefferies (Hong Kong) from 2011 to 2017. Dr. Guo also had extensive international exposure from working as an analyst in the equity research team of HSBC (Hong Kong), Goldman Sachs (Gaohua Beijing) and Goldman Sachs (Singapore).

Dr. Guo obtained a Bachelor of Arts with a major in International Economics from the School of Economics of Nankai University in 1995, a Master of Arts from the School of Economics of Peking University in 1998, and a Master of Philosophy from the Center of Development Studies and Churchill College of the University of Cambridge in 1999. Dr. Guo obtained her PhD from the Judge Business School and Churchill College of the University of Cambridge. Dr. Guo was accredited as a permanent member of the China Independent Non-Executive Directors Association (中國獨立非執行董事協會) in December 2023.

Upon approval of Dr. Guo’s appointment and the relevant ordinary resolution at the AGM, Dr. Guo will enter into a letter of appointment with the Company, pursuant to which Dr. Guo will be appointed as an independent non-executive Director for a term of one year, and is subject to retirement by rotation and re-election at the annual general meetings of the Company and other related provisions as stipulated in the Bye-laws of the Company and the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “**GEM Listing Rules**”). Dr. Guo will be entitled to a director’s fee of HK\$20,000 per month, which was determined by the Board on the recommendation of the Remuneration Committee with reference to her duties and responsibilities, as well as the prevailing market conditions. Dr. Guo will also be entitled to discretionary bonus, share options under share option scheme and share awards under share award scheme to be determined by the Board with reference to her performance and the performance of the Group.

Save as disclosed above, as at the date of this announcement, Dr. Guo (i) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), (ii) did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, or any other major appointments and professional qualifications, (iii) did not hold any other positions with the Company or other members of the Group, (iv) did not have any relationship with any Directors, senior management, substantial or controlling shareholders of the Company, and (v) had not been involved in any of the matters as mentioned under Rules 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules. There is no further information to be disclosed pursuant to the requirements of Rule 17.50(2) of the GEM Listing Rules nor other matters relating to the election of Dr. Guo that need to be brought to the attention of the Shareholders.

Dr. Guo has also confirmed her independence pursuant to Rule 5.09 of the GEM Listing Rules and there are no other factors that may affect her independence in relation to the proposed appointment. The Nomination Committee and the Board have assessed Dr. Guo's independence, and are of the view Dr. Guo has satisfied all the criteria for independence set out in Rule 5.09 of the GEM Listing Rules. The Board is satisfied that the proposed appointment of Dr. Guo was made in accordance with the nomination policy of the Company and the diversity aspects (including without limitation, gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service), and took into account the merits of Dr. Guo, including, among others, her industry knowledge and experience.

The AGM will be held for the purposes of, among other things, seeking the Shareholders' approval on the proposed appointment of Dr. Guo. At the AGM, voting on the proposed ordinary resolution will be conducted by way of poll. The notice of the AGM will be despatched to the Shareholders in due course. A circular containing, among other things, details of the proposed appointment of Dr. Guo as an independent non-executive Director, will also be despatched to the Shareholders as soon as practicable.

By order of the Board  
**China Biotech Services Holdings Limited**  
**Liu Xiaolin**  
*Chairman and Executive Director*

Hong Kong, 13 May 2024

*As at the date of this announcement, the board of Directors comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, and Mr. Huang Song; one non-executive Director, namely, Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from the date of its publication and on the website of the Company at [www.cbshhk.com](http://www.cbshhk.com).*